
    
      This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 (
      COVID-19) infection who are classified as moderate cases and require hospitalization.
      Patients meeting eligibility criteria will be randomized either to receive oral
      N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy
      will be assessed using certain endpoints as follows:

        1. Markers of inflammation and oxidative stress

        2. Length of hospital stay

        3. Need for ventilation

        4. Mortality rate
    
  